1
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*12:384 allele by sequencing-based typing. HLA 2023; 102:538-540. [PMID: 37370209 DOI: 10.1111/tan.15143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 06/19/2023] [Accepted: 06/20/2023] [Indexed: 06/29/2023]
Abstract
HLA-C*12:384 differs from HLA-C*12:03:01:02 by one nucleotide substitution in codon 42 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- Institut d'Immunologie-HLA, CHU de Lille, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- CNRS, INSERM, ImmunoConcEpt, UMR 5164, ERL 1303, Bordeaux University, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
- Institut d'Immunologie-HLA, CHU de Lille, Lille, France
| |
Collapse
|
2
|
Cargou M, Elsermans V, Top I, Ralazamahaleo M, Visentin J. Characterization of the novel HLA-DPB1*1348:01 allele by sequencing-based typing. HLA 2023; 101:313-314. [PMID: 36394166 PMCID: PMC10100256 DOI: 10.1111/tan.14885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 11/13/2022] [Indexed: 11/18/2022]
Abstract
HLA-DPB1*1348:01 differs from HLA-DPB1*14:01:01:01 by one nucleotide substitution in codon 147 in exon 3.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | | | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Lille, France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Université de Bordeaux, CNRS, Immuno Concept, Bordeaux, France
| |
Collapse
|
3
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*17:01:18 allele by sequencing-based typing. HLA 2022; 100:646-648. [PMID: 35920676 PMCID: PMC9804487 DOI: 10.1111/tan.14755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 08/02/2022] [Indexed: 01/05/2023]
Abstract
HLA-C*17:01:18 differs from HLA-C*17:01:01:05 by one nucleotide substitution in codon 18 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance
| | - Vincent Elsermans
- CHU de LilleInstitut d'Immunologie‐HLA, Bd du Professeur Jules LeclercqLilleFrance
| | - Isabelle Top
- CHU de LilleInstitut d'Immunologie‐HLA, Bd du Professeur Jules LeclercqLilleFrance
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance,Univ. Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et ImmunogénétiqueHôpital PellegrinBordeauxFrance,Univ. Bordeaux, CNRS, ImmunoConcEpTBordeauxFrance
| |
Collapse
|
4
|
Wojciechowski E, Cargou M, Guidicelli G, Ralazamahaleo M, Visentin J. Characterization of the novel HLA-C*12:354 allele by sequencing-based typing. HLA 2022; 100:88-90. [PMID: 35261184 DOI: 10.1111/tan.14594] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 03/04/2022] [Indexed: 01/24/2023]
Abstract
HLA-C*12:354 differs from HLA-C*12:03:01:01 by one nucleotide substitution in codon 240 in exon 4. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
5
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*07:01:101 allele by sequencing-based typing. HLA 2021; 98:556-557. [PMID: 34374228 DOI: 10.1111/tan.14395] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 07/24/2021] [Indexed: 11/29/2022]
Abstract
HLA-C*07:01:101 differs from HLA-C*07:01:01:15 by one nucleotide substitution in codon 332 in exon 7.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
6
|
Cargou M, Elsermans V, Top I, Guidicelli G, Visentin J. Characterization of the novel HLA-C*01:214 allele by sequencing-based typing. HLA 2021; 98:481-483. [PMID: 34314104 DOI: 10.1111/tan.14381] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 07/24/2021] [Indexed: 11/26/2022]
Abstract
HLA-C*01:214 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon -10 in exon 1.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Gwendaline Guidicelli
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, Bordeaux, France
| |
Collapse
|
7
|
Cargou M, Elsermans V, Top I, Wojciechowski E, Visentin J. Characterization of the novel HLA-C*15:241 allele by sequencing-based typing. HLA 2021; 98:397-399. [PMID: 34314108 DOI: 10.1111/tan.14383] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 07/24/2021] [Indexed: 11/30/2022]
Abstract
HLA-C*15:241 differs from HLA-C*15:02:01:01 by one nucleotide substitution in codon 48 in exon 2.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, F-33000 Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, F-59000 Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, F-59000 Lille, France
| | - Elodie Wojciechowski
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, F-33000 Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 rue Léo Saignat, F-33000 Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, F-33000 Bordeaux, France.,Univ. Bordeaux, CNRS, ImmunoConcEpT, UMR 5164, 146 rue Léo Saignat, F-33000 Bordeaux, France
| |
Collapse
|
8
|
Cargou M, Elsermans V, Top I, Blouin L, Visentin J. Characterization of the novel HLA-C*06:314 allele by sequencing-based typing. HLA 2021; 98:70-71. [PMID: 33890725 DOI: 10.1111/tan.14282] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 04/20/2021] [Indexed: 11/27/2022]
Abstract
HLA-C*06:314 differs from HLA-C*06:02:01:01 by one nucleotide substitution in codon 327 in exon 7.
Collapse
Affiliation(s)
- Marine Cargou
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Université de Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France
| | - Vincent Elsermans
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Isabelle Top
- CHU de Lille, Institut d'Immunologie-HLA, Bd du Professeur Jules Leclercq, Lille, France
| | - Laura Blouin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France
| | - Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.,Université de Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France
| |
Collapse
|
9
|
Visentin J, Couzi L, Taupin JL. Clinical relevance of donor-specific antibodies directed at HLA-C: A long road to acceptance. HLA 2020; 97:3-14. [PMID: 33052032 DOI: 10.1111/tan.14106] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Accepted: 10/12/2020] [Indexed: 12/21/2022]
Abstract
In solid organ transplantation (SOT), the clinical relevance of donor-specific antibodies (DSA) directed at anti-HLA-A, -B, -DR and -DQ antigens is largely recognized while it is still a matter of debate for DSA directed at HLA-C. In this review, we summarize the peculiarities of HLA-C among class I HLA antigens as well as their immunogenicity, which underlie the clinical relevance of HLA-C locus and anti-HLA-C DSA in SOT. Many factors, both intrinsic and extrinsic to the HLA-C gene and HLA-C protein, explain its lower expression in comparison with HLA-A and -B. This lower expression can explain the apparent lower immunogenicity of HLA-C leading to a lower prevalence and strength of anti-HLA-C antibodies. Nevertheless, HLA-C antigens are truly immunogenic and preformed anti-HLA-C DSA are clinically relevant. Indeed, anti-HLA-C DSA are able to bind donor cells and to activate the complement pathway both ex vivo and in vivo. In line with this, numerous clinical studies now show that preformed DSA directed at native HLA-C molecules induce poorer graft outcomes. We then plead for the inclusion of HLA-C in all transplant allocation systems and we propose a strategy to cope with anti-HLA-C DSA in SOT. Beyond SOT, anti-HLA-C antibodies generate a growing interest in the allo-HCT, transfusion and obstetrics fields, while new concepts such as the role of the "missing-self" in solid organ rejection places HLA-C as an inescapable actor in transplant tolerance.
Collapse
Affiliation(s)
- Jonathan Visentin
- CHU de Bordeaux, Laboratoire d'Immunologie et Immunogénétique, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France.,University of Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France
| | - Lionel Couzi
- University of Bordeaux, CNRS, ImmunoConcEpT, Bordeaux, France.,CHU de Bordeaux, Service de Néphrologie, Transplantation, Dialyse et Aphérèses, Hôpital Pellegrin, Place Amélie Raba Léon, Bordeaux, France
| | - Jean-Luc Taupin
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, Paris, France.,INSERM, UMR976, and Institut de Recherche saint-Louis, Université de Paris, Paris, France
| |
Collapse
|